Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Notice for transferring of equity shares to Investor Education and Protection Fund (IEPF)27-05-2022
27-05-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Audited Financial Results for the quarter and year ended March 31, 202226-05-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Notice for transferring of equity shares to Investor Education and Protection Fund (IEPF)25-05-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Earnings call pertaining to the Financial Results for the Quarter and Financial Year Ended March 31, 2022.25-05-2022
Q4FY22 Quarterly Result Announced for Strides Pharma Science Ltd.
Strides Pharma Science declares Q4FY22 result: All businesses return to growth with visible green shoots Guides for an encouraging FY23 with focus on growth, higher cashflows & reduction in debt Q4 Revenues at Rs 8,699m up 9% and EBITDA at Rs 461m up 100%+ over previous quarter Commenting on the performance, Arun Kumar, Founder, Executive Chairperson & Managing Director remarked, “FY22 has been a challenging year for the pharma industry and, particularly for Strides, given the significant headwinds. We have witnessed unusual price erosion and volume drops in the US, leading to significant compression in our gross margins. The other regulated markets delivered a tepid growth as the business was impacted in H1FY22 due to covid led disruptions. In light of the evolving business environment, we have made several changes to our businesses with a focus on growth, better cash flows and a significant debt reduction. Our growth across the market will be driven by portfolio expansion leveraging our approved portfolio and new customer acquisition for our IP? led B2B businesses. We will aggressively focus on the cost reduction, while one of the key actions planned for the year is to reduce our gross debt by over Rs 10b in FY23, which will bring our Net Debt to EBITDA below 3x. While the operating environment continues to evolve and is ambiguous, we stay confident of a bounce-back in FY23 to deliver significant value for our stakeholders in the coming years.” Result PDF25-05-2022
Strides Pharma Science Ltd - 532531 - Grant Of Options Under Strides ESOP Plan 2016
Pursuant to the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company in their meeting held today i.e., May 24, 2022 has granted 3,50,000 stock options to eligible employees under the Strides ESOP Plan 2016 at Rs. 231/- per option (exercise price). The shares covered by such options are 3,50,000 equity shares. The vesting period of these options is in a phased manner over a period of 3 years. The options are exercisable within a period of 12 months (exercisable in not more than two tranches) from the date of vesting.24-05-2022
Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - Audited Financial Results (Standalone & Consolidated) For The Quarter And Year Ended March 31, 2022
Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for the quarter and year ended March 31, 202224-05-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We write to inform that the Company shall host its earnings call with analysts and investors on Wednesday, May 25, 2022, at 08:30 am IST to discuss the audited financial results of the Company for the quarter and year ended March 31, 2022.23-05-2022